Metformin mitigates placental dysfunction by modulating gene expressions in a high-fat diet-induced rat model

  • Yu Ju Lin
  • , Yin Hua Cheng
  • , Ni Chin Tsai
  • , Li Tung Huang
  • , Hong Ren Yu
  • , You Lin Tain
  • , I. Chun Lin
  • , Kuo Chung Lan*
  • *Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

Background: Maternal obesity impairs placental development and function, contributing to adverse fetal outcomes through disrupted gene regulation and metabolic homeostasis. Metformin, an insulin-sensitizing agent, may mitigate these effects by modulating placental molecular pathways, but its comprehensive impact under obesity-complicated pregnancy remains unclear. Objective: To investigate whether metformin restores placental gene expression and improves placental and maternal metabolic outcomes in a rat model of maternal obesity induced by a high-fat diet (HFD). Methods: Female Sprague-Dawley rats were fed either a control diet or a HFD for six weeks prior to and throughout pregnancy. During gestation, a subset of HFD-fed rats received metformin (500 mg/kg/day) administered via drinking water. Maternal glucose tolerance was assessed in late pregnancy. On gestational day 21, maternal metabolic parameters, placental and fetal weights were assessed. Placental mRNA expression of genes involved in the renin-angiotensin system (RAS), nutrient-sensing (AMPK/SIRT), and nutrient transport (GLUTs, SNATs, AdipoRs) was quantified using qPCR. Results: HFD-fed dams exhibited increased maternal body weight, total fat mass, GPT levels, glucose intolerance, and placental overgrowth. Metformin significantly reversed these effects and improved glucose tolerance without affecting insulin sensitivity. At the molecular level, HFD downregulated key genes involved in RAS, AMPK/SIRT, and nutrient transport. Metformin treatment restored or upregulated the expression of these genes to near-control levels. Conclusion: Metformin mitigates HFD-induced placental dysfunction by restoring vascular, metabolic, and transport gene networks, improving placental efficiency and maternal metabolic status. These findings support metformin's potential to enhance intrauterine conditions in obesity-complicated pregnancies and align with the DOHaD hypothesis, though long-term offspring outcomes require further investigation.

Original languageEnglish
Pages (from-to)114-119
Number of pages6
JournalPlacenta
Volume172
Early online date28 10 2025
DOIs
StatePublished - 12 2025

Bibliographical note

Publisher Copyright:
© 2025 Elsevier Ltd

Keywords

  • High-fat diet
  • Maternal obesity
  • Metformin
  • Nutrient transporters
  • Placenta
  • Renin-angiotensin system

Fingerprint

Dive into the research topics of 'Metformin mitigates placental dysfunction by modulating gene expressions in a high-fat diet-induced rat model'. Together they form a unique fingerprint.

Cite this